Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported pipeline highlights and financial results for
FREMONT, Calif. , Feb. 12, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell , Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018 , to pursue a position as chief executive officer of an early stage biotech start-up company
FREMONT, Calif. , Feb. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb.
FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT .
Favorable Tolerability Profile Demonstrated in 1-year Safety Study FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of
Ardelyx to Receive Up to $125 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company
Ardelyx to Receive a $30 Million Upfront Payment and Subsequent Milestones FREMONT, Calif. and TOKYO , Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, " Kyowa Hakko Kirin "), today announced that they have entered into a license agreement
Company to Host Conference Call at 8:30 a.m. ET Today FREMONT, Calif. , Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia
FREMONT, Calif. , Nov. 7, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017 . "2017 has been a landmark year for Ardelyx , with three statistically significant Phase 3
Preclinical data provide new mechanistic insights linking tenapanor's analgesic action to a well-established pain pathway for the treatment of patients with IBS-C FREMONT, Calif. , Oct. 16, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today reported that data from preclinical studies have